Development of a device to reduce gastro-esophageal reflux in critically ill patients  by Avitzur, Yaron et al.
Clinical Nutrition Experimental 7 (2016) 1e8Contents lists available at ScienceDirect
Clinical Nutrition Experimental
journal homepage: ht tp: / /
www.cl in icalnutr i t ionexper imental .comDevelopment of a device to reduce gastro-esophageal reﬂux
in critically ill patients
Yaron Avitzur a, 1, Peter Vernon van Heerden b, *, 1, Lior Dayan c, Ofer Pintel d,
Jiri Skopek e, Yariv Siman-Tov f, Stephen McClave g, Gianluigi Li Bassi h,
Antonio Torres h, Pierre Singer i
a Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, Canada
b General Intensive Care Unit, Hadassah University Hospital, Jerusalem, Israel
c Pain Institute, Tel-Aviv Sourasky Medical Center, Israel
d LunGuard Ltd., Yavne, Israel
e Thomayer Hospital, 1st Medical Faculty, Department of Biophysics and Informatics, Prague, Czech Republic
f Pre-clinical Research Unit, Asaf Harofe Medical Center, Rishon Lezion, Israel
g Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, USA
h Servei de Pneumologia, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain
i Dept. for General Intensive Care, Rabin Medical Center, Tel Aviv, Israela r t i c l e i n f o
Article history:
Received 22 March 2016
Accepted 5 May 2016
Available online 17 May 2016
Keywords:
Gastro-esophageal reﬂux
Ventilator associated pneumonia
Novel deviceAbbreviations: BP, blood pressure; ECG, electroca
gastro-intestinal tract; GUI, graphic user interface;
nasogastric tube; PFT, peristaltic feeding tube; PVC, po
* Corresponding author. General Intensive Care U
Tel.: þ972 5051 72864.
E-mail addresses: Yaron.Avitzur@sickkids.ca (Y.
com (L. Dayan), pintel.ofer@gmail.com (O. Pintel),
mcclave@louisville.edu (S. McClave), GLIBASSI@cli
(P. Singer).
1 Authors share co-ﬁrst authorship. Both author
http://dx.doi.org/10.1016/j.yclnex.2016.05.002
2352-9393/©2016TheAuthors. PublishedbyElsevie
an open access article under the CC BY-NC-ND licenss u m m a r y
Introduction: Gastro-esophageal Reﬂux (GER) in mechanically
ventilated patients is a contributing factor in the development of
Ventilator-Associated Pneumonia (VAP). In this paper, we report
pilot studies in an animal model and in human volunteers
describing a new Peristaltic Feeding Tube (PFT) comprised of three
balloons integrated into a nasogastric tube which are inﬂated and
deﬂated in a co-ordinated sequential fashion to promote ante-
grade passage of luminal contents through the esophagus into
the stomach.
Materials and methods: In a series of studies involving an animal
model (15 White Landrace pigs of 56e64 kg) and 3 humanrdiogram; GEJ, gastro-esophageal junction; GER, gastro-esophageal reﬂux; GIT,
HR, heart rate; ICU, intensive care unit; MV, mechanical ventilation; NGT,
lyvinylchloride; SpO2, oxygen saturation; VAP, ventilator associated pneumonia.
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the distal balloon was located in the esophagus 3e4 cm proximal
to the gastro-esophageal junction (GEJ), and then continuously
operated for 8e72 h. The PFT was calibrated to ensure a maximum
pressure exerted by the balloons on the internal esophageal wall of
30 mmHg. The anesthetized and mechanically ventilated pigs were
maintained in the supine (8 h study) or the prone position (72 h
study), while the human subjects were awake and maintained in
the semi-recumbent position.
Results: In both an 8 h and a 72 h study, the pigs were stable
throughout, with no evidence of hypotension or hypoxemia,
drooling, inability to manage secretions or vomiting during the
operation of the PFT. Macroscopic evaluation of the esophagus at
the end of study did not reveal erythema, edema, erosions, ulcers
or perforation of the esophageal wall. Histological sections ob-
tained from the esophagus of each animal revealed no damage to
the mucosal surface or at any depth of the esophageal wall, at
either the control sites or at the sites where the PFT balloons had
been active. All three volunteers were stable throughout the 8-
h study period (BP, HR, ECG and SpO2). None reported any pool-
ing of saliva/secretions in the mouth or oro-pharynx or experi-
enced vomiting. Pain/discomfort was reported in the range of 1
e3.5 by subjects on a VAS scale from 0 (no pain) to 10 (worst pain
ever). All three subjects reported on an awareness of the pulsation
of the balloons in the esophagus. Upper GI endoscopy, before and
after the 8-h trial period, failed to demonstrate any esophageal or
gastric mucosal damage.
Conclusions: This PFT device is safe, and may provide an alterna-
tive strategy to prevent GER and perhaps reduce the risk of VAP.
© 2016 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gastro-esophageal reﬂux (GER), common in ventilated patients, occurs when gastric contents
regurgitate into the esophagus [1,2]. Mechanisms that contribute to GER in these patients are: func-
tional derangement of the upper esophageal sphincter [2], use of medications that impair esophageal
motility (such as sedatives, non-depolarizing muscle relaxants, and adrenergic agonists) and naso-
gastric intubation that impairs function of the lower esophageal sphincter [3e5].
GER is also more common in mechanically ventilated patients when they are nursed supine [2]. The
semi-recumbent position has therefore been introduced into clinical practice as part of a “bundle of
care” to hinder GER and avoid subsequent oropharyngeal colonization and pulmonary aspiration of
pathogens originating lower in the gastro-intestinal tract (GIT) [6e8].
Ventilator-associated pneumonia (VAP) is a hospital-acquired infection in patients receiving me-
chanical ventilation (MV) for at least 48 h [6]. VAP prolongs the time onMV and the length of stay in the
intensive care unit (ICU) and in the hospital andworsens patient outcome [9e11]. Growth of pathogens
in the stomach is encouraged by alkalinization of gastric contents by enteral nutrition and medications
[12]. During GER ﬂuid containing micro-organisms from the GIT may reach the oropharynx. These
organisms are aspirated into the airways across the endotracheal tube (ETT) cuff (between the cuff and
the tracheal wall) [13,14].
Given the role of GER in the causation of VAP, there is a strong need for a device that prevents GER
during mechanical ventilation. The peristaltic feeding tube (PFT) (LunGuard Ltd. Yavne, Israel) provides
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The device is designed to decrease GER. The PFT replicates a conventional nasogastric feeding tube, but
adds a feature of simulated peristalsis within the lumen of the distal esophagus. This peristalsis seals
the esophagus to ﬂuid moving in a retrograde fashion (like GER), while allowing normal drainage of
ﬂuid and secretions moving in an ante-grade fashion. The peristaltic motion is derived from syn-
chronized cyclical inﬂation and deﬂation of three balloons at the distal end of the PFT, governed by an
external control unit. When the PFT was placed in a clear polyvinyl chloride (PVC) tube of similar
diameter to the adult human esophagus (20 mm) and the controller was activated, a bolus of viscous
ﬂuid colored with food dye introduced above the proximal balloon of the PFT was shown to pass in an
ante-grade fashion during peristaltic motion of the balloons, with total lack of retrograde ﬂow.
This paper describes the development of the PFT device to date, including in-vivo animal studies and
a human volunteer study.
2. Materials and methods
Animal ethics committee approval for the animal studies and institutional ethics review board
approval for the human volunteer study were obtained.2.1. The PFT device and controller
The PFT is a 130 cm long tube of 5 mm external diameter and is made of medical grade silicone. It is
designed to be placed, via the nose, into the stomach like a conventional nasogastric tube (NGT). It is
supplied sterile and ﬁtted with a guide-wire in the central lumen to enhance rigidity during insertion.
The guide-wire is removed after insertion. The tube has a central channel (internal diameter 3 mm) for
either drainage of the stomach or to be used for the administration of enteral medications or nutrition.
At the distal end of the PFT there are three inﬂatable balloons, the distal balloon being 15 cm from the
tip of the PFT (Fig.1a and b). These are completely deﬂated during insertion and removal of the PFT. The
balloons are attached to an external pneumatic control unit via a hollow connecting line, each balloon
separately.
The external pneumatic controller governs the inﬂation and deﬂation of the balloons in a cyclical
synchronous fashion, from proximal balloon to distal balloon, to produce a peristaltic motion in the
direction of the stomach (Fig. 1c). At least one balloon is inﬂated at all times, providing a mechanical
barrier to the movement of ﬂuid in a retrograde manner, from the stomach into the esophagus. TheFig. 1. Peristaltic feeding tube (PFT) and controller. a e The peristaltic feeding tube, with all three balloons inﬂated. b e Schematic
diagram of the peristaltic feeding tube and controller. c e The external controller and monitor of the peristaltic feeding tube.
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well as regulating the duration of inﬂation of each balloon. It is also equipped with alarms to allow for
the safe operation of the balloons in the esophagus, such as high pressure alarms and an automatic
shut-off feature in the event of over-pressure (such as may occur during coughing, straining or vom-
iting). The graphic user interface (GUI) allows easy visualization and control of the device. The external
controller is designed to be placed on a stand (e.g. intravenous solution hanger pole) or a surface near
the patient.
The PFT was placed by observing the increase in pressure in the distal balloon as it transitioned (was
withdrawn) from the stomach into the narrower esophagus. For the purposes of the study the position
of the PFT was then conﬁrmed by ﬂuoroscopy, so that the distal balloon of the PFT was located in the
esophagus 3e4 cm proximal to the gastro-esophageal junction (GEJ). The PFT was calibrated, using a
proprietary technique, in-vivo, to ensure that the maximum pressure exerted by the balloons against
the esophageal wall was never greater than 30mmHg. This maximumpressurewas chosen, so as not to
compromise capillary ﬂow to the esophageal mucosa, while providing an effective barrier to GER. This
pressure was applied at the site of each balloon for less than 10 s (the entire inﬂation and deﬂation
cycle of each balloon) at a time. The inﬂation of each successive balloon overlapped slightly (1e2 s)
with the deﬂation of the previous balloon, so that there was no period with all the balloons completely
deﬂated during the operation of the PFT, in order to maintain a constant physical barrier against reﬂux.
2.2. Animal studies
Two sequential animal studies were performed using the same animal model (white Landrace pigs
weighing 30e64 kg), testing operation of the PFT device for 8 h and then 72 h in duration. The ﬁrst trial
(8 h duration) was carried out at the Assaf Harofe Medical Center, Israel. Eleven pigs were anesthetized,
intubated, and placed on mechanical ventilation. The anesthetized pigs were maintained in the supine
position. The PFT was inserted as described above and allowed to operate continuously for a minimum
of 8 h. Vital signs were monitored every 15 min to ensure stability of temperature and hemodynamic
and respiratory parameters. At the end of this period, the anesthetized animals were euthanized with
intravenous potassium chloride and the esophagus removed en-bloc with the PFT still in place. Full
thickness tissue cross-sections of the esophagus were taken from each animal as follows e above and
below the level of the balloons of the PFT (as control sections) and at the mid-position of each balloon;
a total of 5 sections from each animal. This sampling site selection was used to determine if the action
of the balloons of the PFT resulted in any damage to the esophageal mucosa (or deeper structures of the
esophagus). Each of these areas was inspected macroscopically for signs of damage to the esophageal
mucosa, and then the sections were prepared for histologic evaluation by an expert histo-pathologist.
The second trial was carried out in the animal laboratory of the Hospital Clínic de Barcelona, Bar-
celona, Spain. This time, four pigs were prepared in a similar fashion, but kept on continuous operation
of the PFT for 72 h. Anesthesia was maintained with a continuous infusion of midazolam, 0.2e0.8 mg/
Kg/h, and fentanyl 5e10 mg/Kg/h. Boluses of 50 mg of intravenous sodium thiopental were adminis-
tered as needed. Under strict aseptic conditions, the femoral artery was cannulated for systemic arterial
pressure monitoring and collection of blood samples. A three-lumen, venous catheter was introduced
into the femoral vein to measure central venous pressure and allow systemic infusion of drugs. A Foley
catheter was inserted into the urinary bladder to monitor urine output. The anesthetized pigs were
placed in the prone position with the operating table oriented at 30 above the horizontal to simulate
the semi-recumbent position in humans.
In order to prevent pneumonia, caused by aspiration of endogenous oro-pharyngeal ﬂora, 1 g of
Ceftriaxone was administered before intubation and then 50 mg/kg every 12 h for the duration of the
study. Every 6 h the mechanical ventilator was disconnected and the trachea was suctioned using a 10
Fr. Gentle-Flo® suction catheter (Mallinckrodt Inc, St. Louis, MO). The suctionedmaterial was not tested
at all. This procedure was merely to prevent the accumulation of secretions in the airway. The pigs
received a continuous IV infusion of glucose 5% to maintain blood glucose between 70 and 80 mg/dl
and 0.9% sodium chloride and Ringer's lactate solution to maintain hydration (1:1 ratio).
Gas exchange, pulmonary mechanics, hemodynamics, urine output and ventilator settings were
assessed every 6 h. Every 12 h, complete blood count, a basic metabolic panel, liver function tests, a
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parameters and results are therefore not reported. Seventy-two hours after placement of the PFT, the
animals were euthanized and tissue samples obtained and analyzed as described above (macroscopic
review and histological examination).
2.3. Human volunteer study
The human trial was carried out in three healthy, adult male volunteers (ages 22, 29 and 45 years) at
the Thomayer University Hospital in Prague, Czech Republic. All volunteers provided written informed
consent. Subjects underwent upper gastrointestinal endoscopy under topical anesthesia before
placement of the PFT and after its removal. The PFT was then operated via the control unit for at least
8 h in each subject.
Subjects were awake and maintained in the semi-recumbent position after insertion of the PFT.
Blood pressure (BP), heart rate (HR), continuous electrocardiography (ECG) and pulse-oximetry (SpO2)
were used to monitor the patients throughout the trial. Subjects were also asked to report on the
sensation of saliva pooling in the mouth or oropharynx, as well as reporting hourly on any pain or
discomfort using a visual analogue score (VAS), rated from 0 (no pain) to 10 (worst pain ever expe-
rienced). Throughout the duration of the trial subjects read, watched TV/videos or listened to music.
3. Results
3.1. Animal studies
In both the 8 h study and the 72 h study, the pigs were stable throughout the period of the study,
with no evidence of hypotension or hypoxemia. There was no evidence of drooling, inability tomanage
secretions or vomiting during the operation of the PFT. Macroscopic evaluation of the esophagus at the
end of both the 8 h study and the 72 h study failed to reveal any signs of erythema, edema, erosions,
ulcers or perforation of the esophageal wall. Histological sections obtained from the esophagus of each
animal at the end of the two study periods, examined by expert histo-pathologists, revealed no damage
to the mucosal surface or at any depth of the esophageal wall, at either the control sites or at the sites
where the PFT balloons had been active. Figure 2 is representative of a histological section of the
esophagus of a subject taken at the level of one of the balloons of the PFT, in comparison to a control
section.
3.2. Human study
All three volunteer subjects were stable throughout the 8-h study period with regard to BP, HR, ECG
and SpO2. None reported any pooling of saliva/secretions in the mouth or oro-pharynx, and no one
experienced vomiting. Pain/discomfort was reported in the range of 1.0e3.5 by the subjects using the
VAS. All three subjects reported an awareness of the pulsation of the balloons. Upper GI endoscopy,
before and after the 8-h trial period failed to demonstrate any esophageal or gastric mucosal damage.
4. Discussion
This paper reports on the development of a novel device, the peristaltic feeding tube (or PFT), to
reduce gastro-esophageal reﬂux in subjects who already have a requirement for placement of a naso-
gastric tube, such as critically ill ventilated patients. The PFT was trialed in an animal model and in
healthy human volunteers.
We believe that the device is effective in causing uni-directional ﬂow of secretions from the
esophagus to the stomach, as evidenced by the lack of pooling of saliva/secretions in the mouth or
oropharynx of the animal and human subjects, despite the presence of an obstructing device in the
esophagus (both the central feeding tube and the fact that at least one balloon is inﬂated at all times
would present an obstruction if the device was not functioning properly). Testing of the device in vitro
in a clear PVC tube, as mentioned in the introduction, further conﬁrms unidirectional ﬂow of ﬂuid
Fig. 2. Representative histology sections of the esophageal wall showing no damage to the esophagus at the level of the balloons
(Fig. 2a) versus a control section (Fig. 2b). H&E stain. a e Section taken at the level of the peristaltic balloon. b e Control section.
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function reliably for prolonged periods, without causing any tissue damage to the esophagus due to the
cyclical pressure-limited inﬂation of the balloons of the PFT. Volunteers who are awake report that the
device is easy to tolerate, allowing us to assume that the device will be well-tolerated in sedated and
ventilated patients, who will be the main recipients of this device.
In all subjects the device was as easy to insert as a standard NGT. In all the animal subjects the PFT
was found to be in a suitable positionwhen the esophagus was harvested and opened at the end of the
study procedure, essentially being in the same position as indicated by the initial radiographic
conﬁrmation of placement. The PFT therefore did not migrate in the esophagus during the study
period. None of the human volunteers described the sensation of the PFT migrating distally, nor did the
depth marker of the PFT at the nares vary at all during the study period. Fixation of the PFT at the nares
of volunteers and at the snout of the animal subjects was done in the samewaywe ﬁx nasogastric tubes
in our patients (note the depth of the tube and ﬁx with adhesive tape or similar material).
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shown that the device is practically feasible and safe we have yet to show that in critically ill patients
receiving mechanical ventilation it prevents or reduces GER. This is the subject of a current study
where the device is employed in ventilated patients in the intensive care unit and the incidence of
reﬂux is being determined by using pepsin as a marker i.e. do secretions containing pepsin (produced
in the stomach) reach the oro-pharynx and/or trachea of ventilated patients who have a functioning
PFT, versus those with a sham device?
The device has so far been trialed only in stable anaesthetized animals and in healthy volunteers
who have normal tissue oxygen tension and normal esophageal mucosal perfusion. The PFT device
does not cause damage in these settings because the contact pressure between the peristaltic balloons
and the mucosa is limited to less than 30mmHg. However, we are cognizant of the fact that both tissue
oxygen tension andmucosal perfusionmay be impaired in critically ill patients. For this reason the next
phase of development of the device will be in critically ill ventilated patients to determine both safety
and efﬁcacy in this setting.
We are hopeful that if the PFT can reduce GER, thenwewill see an associated reduction in VAP. This
hope is based on the efﬁcacy in reducing GER and VAP by the simple already-proven maneuver of
nursing patients in the semi-recumbent position as compared to the supine position [2,6e8] i.e. using
the effect of gravity to reduce GER. Indeed this recommendation has been introduced into many
bundles of care for ventilated patients to reduce GER and VAP [15]. By providing a physical barrier to
GER the PFT should provide similar or better protection than gravity alone against GER and VAP.
Further study into the efﬁcacy of the device is proceeding, based on the initial studies described in
this paper. Brieﬂy, the efﬁcacy study underway in a cohort of critically ill ventilated patients is using an
esophageal pH probe to detect GER, as well as sampling the oropharynx and the trachea for pepsin
originating in the stomach. Once proven to be efﬁcacious, further study will be required to link the
expected reduction in GER afforded by the device to a reduction in VAP. This will be the subject of
another study.
The features described above (limiting balloon inﬂation time and pressure) have been shown to be
safe in an animal model (for 8 h and then for 72 h) and also in awake human volunteers. To our
knowledge, there are no similar devices on the market at present.5. Conclusion
We are encouraged that we have produced a device which is safe and which, with further study,
may provide an alternative strategy to prevent GER and thereby reduce the risk of VAP.Statement of authorship
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